China Approves SinoVac's CoronaVac, As 50.6% Efficacy Reported
Slow Roll-Out Despite Looming New Year Holiday
SinoVac has obtained conditional approval in China for its COVID-19 vaccine CoronaVac, while new clinical data released by the company show a large difference in protection rates in two separate trials, in one case barely above the WHO threshold.
